New immunomodulators of BTLA-HVEM complex as potential therapeutics in systemic lupus erythematosus
2021/43/B/NZ7/01022
Keywords
Descriptors
- NZ5_003: Patogeneza chorób człowieka
- NZ5_007: Leczenie chorób człowieka
- NZ7_016: Inne zagadnienia pokrewne
Panel
NZ7 – Diagnostic tools, therapies and public health: public health, epidemiology, environmental health risks and occupational medicine, medical ethics, drug discovery and therapies, pharmacology
Host institution
Gdański Uniwersytet Medyczny, Wydział Lekarski
Voivodeship: pomorskie
Principal investigator (from the host institution)
Number of co-investigators in the project: 7
Call
OPUS 22 – announced on 2021-09-15
- Amount awarded
- 1 904 664 PLN
- Project start date
- 2022-07-15
- Project end date
- 2027-07-14
- Project duration
- 60 months (the same as in the proposal)
- Project status
- Pending project
Project description
Download the project description in a pdf file
Note — project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.
Information in the final report
Publication in academic press/journals (1)
-
Peptides targeting the BTLA-HVEM complex can modulate T cell immune response
- Authors:
- Wojciechowicz K, Kuncewicz K, Lisowska KA, Wardowska A, Spodzieja M.
- Academic press:
- European Journal of Pharmaceutical (year: 2024, volume: 193, pages: 106677), Publisher: Elsevier
- Status:
- Published
- DOI:
- 10.1016/j.ejps.2023.106677 – link to the publication